1 ASCO Annual Meeting 2013 Poster presentation January 2013.

Slides:

Advertisements

Similar presentations

First Efficacy Results of a Randomized, Open- Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without.

Advertisements

13th Annual Hematology & Breast Cancer Update Update in Lymphoma

Joint Hospital Surgical Grand Round Accelerated partial breast irradiation: where should we go? Dr Ma Kwok Kuen Queen Mary Hospital.

Analysis of risk factors predicting time to development of brain metastases presented at the 44 th Annual ASCO Meeting, June , McCormick.

Breast Cancer Screening, Family History Assessment and New Innovations Miss Karina Cox Consultant Breast and Oncoplastic Surgeon.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

Neoadjuvant Adjuvant Curative Palliative Neoadjuvant Radiation therapy the results of a phase III study from Beijing demonstrated a survival benefit.

Hot topics in breast radiotherapy Mark Beresford.

Meta-analysis of trials of radiotherapy in DCIS Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)

Controversies in the management of PSA-only recurrent disease Stephen J. Freedland, MD Associate Professor of Urology and Pathology Durham VA Medical Center.

Study Of Letrozole Extension

Hypofractionated Radiation Therapy for Early Stage Breast Cancer Patrick J. Gagnon, M.D. Resident, PGY-4 Radiation Medicine, OHSU Providence Hospital Breast.

6 months versus 12 months of adjuvant trastuzumab for patients with HER2- positive early breast cancer (PHARE): a randomised phase 3 trial Speaker: 陳鴻明.

These slides were released by the speaker for internal use by Novartis.

Neoadjuvant versus Adjuvant Systemic Treatment in Breast Cancer: A Meta-Analysis Mauri D, Pavlidis N, Ioannidis J. J Natl Cancer Inst 2005;97(3):

Surrogate Endpoints and Correlative Outcomes Hem/Onc Journal Club January 9, 2009.

Surrogate End point for Prostate Cancer- Specific Mortality After RP or EBRT A D’Amico J Nat Ca Inst 95,

Controversies in Radiation Therapy for Breast Cancer?

The Impact of Capecitabine and Oxaliplatin in the Preoperative Multimodality Treatment of Patients with Carcinoma of the Rectum: NSABP R-04 1 Capecitabine.

Clinical Trials Evaluating the Role of Sentinel Node Resection in Patients with Early-Stage Breast Cancer Krag DN et al. Proc ASCO 2010;Abstract LBA505.

Evidence Based For invasive breast cancer BCT is Tumor excision, axillary node dissection, whole breast radiation Modified mastectomy is total mastectomy.

Targeted Intraoperative Radiotherapy versus Whole Breast Radiotherapy for Breast Cancer (TARGIT-A Trial): An International, Prospective, Randomised, Non-Inferiority.

Best first ? The ATAC completed treatment analysis Professor Jack Cuzick Wolfson Institute of Preventive Medicine, London, UK.

Flow Diagram of the Main HOPE Trial and the HOPE-TOO Trial Extension The HOPE and HOPE-TOO Trial Investigators JAMA. 2005;293:

Delivering clinical research to make patients, and the NHS, better OG neoadjuvant therapy Brachytherapy Stephen Falk dd/mm/yyyy.

Radical Mastectomy is no longer the standard Improved adjuvant and neoadjuvant therapy Chemotherapy Endocrine therapy Radiation treatment Reconstruction.

New York University Department of Radiation Oncology Prospective Randomized Trial of Prone Accelerated Intensity Modulated Whole Breast Radiation Therapy.

EARLY PROGRESSION IN PATIENTS WITH HIGH-RISK SOFT TISSUE SARCOMAS AN ANALYSIS FROM A PHASE III RANDOMIZED PROSPECTIVE TRIAL (EORTC 62961/ESHO) OF NEOADJUVANT.

on behalf of the ACOSOG Z4032 Investigators

Final Analysis of Overall Survival for the Phase III CONFIRM Trial: Fulvestrant 500 mg versus 250 mg Di Leo A et al. Proc SABCS 2012;Abstract S1-4.

Clinical Case Nº2 Dr. Javier Martín-Broto. Case description 49-year-old man 1 st symptom/sign: Mild pain in right buttock 1 st diagnosis: Core-biopsy:

Evidence for a Survival Benefit Conferred by Adjuvant Radiotherapy in a Cohort of 608 Women with Early-stage Endometrial Cancer O. Kenneth Macdonald 1,

FREEDOM FROM PROGRESSION FOR PATIENTS RECEIVING I 125 VERSUS Pd 103 FOR PROSTATE BRACHYTHERAPY Jane Cho, Carol Morgenstern, Barbara Napolitano, Lee Richstone,

Time to Secondary Resistance (TSR) After Interruption of Imatinib: Updated Results of the Prospective French Sarcoma Group Randomized Phase III Trial on.

‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial: Completed Treatment Analysis.

Four vs 6 Cycles of Doxorubicin and Cyclophosphamide (AC) or Paclitaxel (T) as Adjuvant Therapy for Breast Cancer in Women with 0-3 Positive Axillary Nodes:

Extranodal Extension on Sentinel Lymph Node Dissection: Why Should We Treat It Differently? Audrey Choi MD, Matthew Surrusco MD, Samuel Rodriguez MD, Khaled.

Combined Modality Treatment of Locally Advanced Prostate Cancer: Radiation Therapy (RT) with Concurrent Androgen Deprivation Therapy (ADT) Howard Sandler.

HERA TRIAL: 2 Years versus 1 Year of Trastuzumab After Adjuvant Chemotherapy in Women with HER2-Positive Early Breast Cancer at 8 Years of Median Follow-Up.

Journal Club Dr. Eyad Al-Saeed Radiation Oncology 12 January, 2008.

Refining Radiotherapy for Early Breast Cancer: The Challenges. David Dodwell Radiotherapy in Practice Sheffield Hallam University October 2010.

Neuropathy Is Not Associated With Clinical Outcomes in Patients Receiving Adjuvant Taxane-Containing Therapy for Operable Breast Cancer Bryan P. Schneider,

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial Aron Goldhirsch, Richard.

R1 강민혜 / prof. 전숙. Introduction Patients with type 2 diabetes have a greatly increased risk of cardiovascular events. The morbidity and mortality related.

Neoadjuvant chemotherapy in the treatment of NSCLC Department of Thoracic Oncology, University Hospital Ghent, Belgium Current Opinion in Oncology 2007,

방사선종양학과 - 혈액종양내과 Joint Conference 경희의료원 방사선종양학과 R4 공 문 규.

Ο ρόλος των μη χειρουργικών θεραπειών στο μη μεταστατικό μυοδιηθητικό καρκίνο ουροδόχου κύστεως Γεώργιος Δ. Λύπας Παθολόγος Ογκολόγος Α’ Ογκολογική Κλινική.

12 th Annual CTOS Meeting 2006 SINGLE AGENT DOXORUBICIN VS DOSE INTENSIVE COMBINATION THERAPY WITH EPIRUBICIN / IFOSFAMIDE IN PREVIOUSLY UNTREATED ADULT.

Emily Tanzler, MD Waseet Vance, MD

Figure #1 Overall survival Figure #2 Disease free survival

JOURNAL OF CLINICAL ONCOLOGY 25:

Definitive Analysis of the Primary Outcomes

Single center experiences with intraoperative radiotherapy (IORT) as a boost during oncoplastic breast-conserving surgery Malter W¹, Puppe J¹, Rogée K¹,

Presented By Marco Colleoni at 2017 ASCO Annual Meeting

Figure 1. (a) Dose distribution of dynamic conformal photon therapy

Figure 1 Overall survival and cause-specific survival after breast conservation treatment with radiation for 1003 patients with mammographically detected.

Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: Combined results.

Volume 378, Issue 9804, Pages (November 2011)

Untch M et al. Proc SABCS 2010;Abstract P

Volume 383, Issue 9917, Pages (February 2014)

Volume 376, Issue 9735, Pages (July 2010)

Management of endometrial cancer found on routine hysterectomy for benign disease Prof Dr M Anıl Onan MAY ANTALYA.

Neoadjuvant Adjuvant Curative Palliative

THE LANCET Oncology Volume 19, No. 1, p27–39, January 2018

Proton Therapy for Thymic Malignancies: Multi-institutional Patterns-of-Care and Early Clinical Outcomes from the Proton Collaborative Group Registry &

Presentation transcript:

1 ASCO Annual Meeting 2013 Poster presentation January 2013

2 5 years results: 734 patients, 7 centres in Germany Absolute number of events in TARGIT vs. EBRT : Primary outcome: IBR 4 vs. 1 Exploratory outcome: All recurrences (breast +axilla+contralateral+distant recurrence) 11 vs. 7 Secondary outcome: All deaths 6 vs. 12 Breast Cancer deaths 3 vs. 5 Non-Breast Cancer deaths 3 vs. 7 Message: The 734 German patients have excellent 5 year outcomes in both arms of the trial Survival was better in TARGIT than in EBRT Source: J Clin Oncol 31, 2013 (suppl; abstr 1121) TARGIT-A trial: Updated results for local recurrence and survival for the German centers Presenter: Frederik K. Wenz January 2013

3 Matched pair analysis impact on overall survival of IORT boost vs. EBRT boost : 370 patients with 53 pairs Medium Follow up: 56 month in IORT vs. 6 month in EBRT Strong trend towards better overall survival after IORT boost (90.2% vs. 62.3%, p = 0.375) IBR 1 vs. 1 Message: IORT given as a boost seems to have a positive impact on overall survival in breast cancer patients after breast conserving surgery Source: J Clin Oncol 31, 2013 (suppl; abstr 1120) Intraoperative versus external beam boost for breast cancer: A matched-pair analysis Presenter: Elena Sperk January 2013

4 Single center experience since 2006 IORT only vs. WBRT in low risk early breast cancer patients (in patients with high risk tumor characteristics at final pathology, additional local breast therapy) 400 patients Medium Follow up: 30 month (43 months in the first 200 patients) Seven ipsilateral breast failures (1.7%) and one axillary recurrence were observed Message: Center concludes that intraoperative radiotherapy using the Intrabeam system is feasible and may offer an alternative to whole breast RT in low risk breast cancer patients Clinically significant local morbidity rate is low Source: J Clin Oncol 31, 2013 (suppl; abstr 1108) Intraoperative radiotherapy in early breast cancer: 400 consecutive patients in one institution Presenter: Mariana Steiner January 2013

5